CONSULTING AGREEMENTConsulting Agreement • August 29th, 2024 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Consulting Agreement (the “Agreement”), effective as of the Effective Date (as defined herein), is entered into between Karyopharm Therapeutics Inc. (the “Company”) and Michael Mason (the “Consultant”). The Consultant and the Company are referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
TRANSITION AGREEMENTTransition Agreement • August 29th, 2024 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Transition Agreement (the “Agreement”) is made as of August 29, 2024 (“the Agreement Effective Date”) by and between Karyopharm Therapeutics Inc. (the “Company”) and Michael Mason (“Executive”) (together, the “Parties”). Capitalized terms used but not defined herein have the meanings set forth in the 2019 Offer Letter by and between Executive and the Company, as most recently amended on May 24, 2021 (the “Offer Letter”).
